Ayala Pharmaceuticals News
26 articles
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
Ayala Pharmaceuticals, a clinical-stage oncology company, announced that it has filed a Form 15 with the SEC to deregister its common stock and suspend its reporting obligations under the Exchange Act. This means the company will no longer be required to file periodic reports such as Forms 10-K, 10-Q, and 8-K. The deregistration is expected to be effective within 90 days of filing. This move indicates that Ayala Pharmaceuticals will no longer be a public reporting company.
Public Trading
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Ayala Pharmaceuticals, a clinical-stage oncology company, announced the completion of its merger with Biosight, Ltd. The combined entity will continue to operate under the name Ayala Pharmaceuticals, Inc., and its shares will trade on the OTCQX under the ticker symbol ADXS. The merger expands Ayalas product pipeline, adding aspacytarabine (BST-236), a novel antimetabolite in clinical development for AML. The companys primary focus remains on completing the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. The existing senior management team of Ayala will lead the combined company, with some new appointments from Biosight. The merger is expected to bring synergies and growth opportunities.
AcquisitionManagement Changes
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Ayala Pharmaceuticals and Biosight Ltd. have announced a definitive merger agreement. The combined company will operate under the name Ayala Pharmaceuticals and will continue to trade on the OTCQX under Ayala’s current ticker symbol. The merger will add a clinical stage oncology asset to Ayala’s portfolio. The combined company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102 and Biosight’s Aspacytarabine (BST-236). The merger is expected to close prior to the end of the third quarter of 2023.
Acquired-byManagement Changes
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
Ayala Pharmaceuticals, previously known as Advaxis Inc., has announced its financial results for the fiscal year ending October 31, 2022. The company closed its merger in January 2023 and is now focused on the development and commercialization of AL102 for the treatment of desmoid tumors. The company reported revenues of $250,000 for the fiscal year 2022, compared to $3.2 million for the fiscal year 2021. The net loss for the fiscal year ended October 31, 2022, was approximately $14.4 million.
Acquired-byManagement Changes
Advaxis and Ayala Pharmaceuticals Complete Merger
Advaxis, Inc. has completed a merger with Ayala Pharmaceuticals, Inc. The merged company will operate under the name Ayala Pharmaceuticals and will focus on the development and commercialization of Ayalas lead program AL102 for the treatment of desmoid tumors. Advaxis is seeking to uplist to Nasdaq in the near future. The management and board of directors of the merged company have been announced. Ayala Pharmaceuticals is primarily focused on developing and commercializing small molecule therapeutics for rare tumors and aggressive cancers. Their lead candidates under development are AL102 and ADXS-504. AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 portion of a pivotal study for patients with desmoid tumors.
AcquisitionManagement Changes
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
Ayala Pharmaceuticals, a clinical-stage oncology company, has announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). The Phase 3 segment of RINGSIDE is a double-blind, multi-center trial enrolling up to 156 patients with progressive disease. Positive interim data from Part A, the Phase 2 segment of RINGSIDE were presented at ESMO in September 2022. AL102 received Fast Track designation from the U.S. FDA granted in September 2022 for the treatment of progressing desmoid tumors.
Customers
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Ayala Pharmaceuticals and Advaxis have announced a definitive merger agreement. The merger will result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer. Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company’s outstanding common stock and Advaxis stockholders will own approximately 37.5%. The combined company plans to seek uplisting to Nasdaq.
Acquired-byManagement ChangesPublic Trading
Ayala Pharmaceuticals raises $55m in Nasdaq IPO
Israeli biotech company Ayala Pharmaceuticals has raised $55 million in a fundraising round on Nasdaq. The company is developing Notch inhibitors for aggressive cancers that are in Phase II trials. Ayala Pharmaceuticals specializes in the treatment of a certain type of cancer that presents Notch pathway mutations. The recent fundraising round was led by pharmaceuticals company Novartis, which has previously invested in Ayala and may be interested in collaborating with them in the future. The companys share price ended its first day of trading up 0.03% at $15.03, giving a market cap of $182.1 million.
Investment
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
Ayala Pharmaceuticals, a clinical-stage oncology company, has announced the pricing of its initial public offering (IPO) of common stock. The IPO consists of 3,666,667 shares of common stock at a price of $15.00 per share. The offering is expected to close on May 12, 2020, and Ayala has granted the underwriters a 30-day option to purchase additional shares. The gross proceeds of the offering are expected to be $55.0 million. Ayalas common stock will begin trading on the NASDAQ Global Market under the ticker symbol AYLA on May 8, 2020. Citigroup and Jefferies are the lead book-running managers for the offering, with Oppenheimer & Co. and Raymond James acting as co-managers.
Public Trading
Ayala Pharma files for Nasdaq IPO
Israeli-US cancer treatment company Ayala Pharmaceuticals has filed a draft prospectus for an IPO on Nasdaq, seeking to raise $50 million. The company has not disclosed its valuation for the IPO, but it is expected to be in the hundreds of millions of dollars. The underwriters for the IPO are Citi, Jefferies, Oppenheimer, and Raymond James. Ayala Pharmaceuticals was founded by venture capital firms IBF and aMoon, and has raised $70 million so far. The company is developing treatments for cancers involving the Notch mutation. It has received products from Bristol-Myers Squibb and has signed a licensing deal with Novartis. Ayala Pharmaceuticals posted a loss of $17 million in 2019, mainly due to research and development expenses.
Public Trading
Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
Ayala Pharmaceuticals Headed for Nasdaq IPO
Israel-based Ayala Pharmaceuticals Inc. plans to raise $100 million through a Nasdaq IPO. The company, which is valued at $400 million, is a precision oncology company developing targeted therapies for rare cancers. Ayala has tapped Citi Bank and Jefferies Group LLC to lead the IPO. It has previously raised $52.60 million in funding, with investors including Novartis International AG, Israel Biotech Fund, Harel Insurance Investments & Financial Services Ltd., and aMoon.
InvestmentPublic Trading
Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)
Ayala Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that a poster will be presented at the European Society for Medical Oncology (ESMO) in Barcelona, Spain from September 27 to October 1, 2019. The poster will detail the phase 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic adenoid cystic carcinoma patients with Notch activating mutations.
None
Ayala Pharma nabs AbbVie cancer exec Gordon as CMO
The article discusses the terms of use and privacy policy of Questex LLC.
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
ArcherDX and Ayala Pharmaceuticals have announced a strategic collaboration to develop companion diagnostic tests targeting cancers with Notch activating mutations and fusions. The partnership aims to bring biomarker-driven therapies to cancer patients and improve access to genomic-based medicine. ArcherDX, a molecular technology company, will provide companion diagnostic solutions from both tissue and blood-based specimens. Ayala Pharmaceuticals, a precision oncology company, is developing targeted therapies for genetically defined cancers. The collaboration will support Ayala in their pursuit of precision oncology treatment options.
Partners
Cancer drug developer Ayala Pharmaceuticals raises $30m
Ayala Pharmaceuticals Inc., an Israeli clinical-stage company developing medicines for genetically defined cancers, has completed a $30 million Series B financing round. The investment was led by Novartis and included participation from SBI JI Innovation Fund and all existing investors. The funds will be used for the clinical development of AL101, a pan-Notch inhibitor currently being evaluated for adenoid cystic carcinoma (ACC). The company also plans to initiate a Phase II clinical trial in triple negative breast cancer (TNBC).
Investment
Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer
FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
Ayala Pharmaceuticals, Inc. will present new data for AL101, a potential therapy for adenoid cystic carcinoma (ACC) with Notch activating mutations, at the 2019 American Association for Cancer Research (AACR) Annual Meeting. The data shows that AL101 has a significant effect on tumor growth inhibition in ACC patient-derived xenograft (PDX) tumors with Notch activating mutations. These results support the clinical development of AL101 as a targeted monotherapy for ACC tumors with Notch activating mutations. Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies for genetically defined cancers.
Customers
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
Pharma multinational Novartis International AG has made a $10 million equity investment in Ayala Pharmaceuticals Inc., a clinical-stage company developing targeted therapies for genetically-defined cancers. The investment is part of a licensing option agreement between the two companies. Novartis will evaluate one of Ayalas drug candidates for the treatment of multiple myeloma, while Ayala retains licensing rights for all other indications of the drug.
Investment
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17
Cancer drug developer Ayala Pharmaceuticals raises $17m
Israeli oncology drug development company Ayala Pharmaceuticals has raised $17 million in a Series A financing round. The funds will be used for the first Phase II study in recurrence or metastatic Adnoid Cystic Carcinoma (ACC) patients with activated Notch pathway and for conducting preclinical research. Ayala Pharmaceuticals expects the results of the Phase II trial for ACC in the first half of 2019. The company is also exploring the use of the drug in treating triple-negative breast cancer.
Investment
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
